Work

Anaemia management in patients with chronic kidney disease: a position statement by the Anaemia Working Group of European Renal Best Practice (ERBP)

Year: 2008
Type: article
Abstract: Over the last few years, much has been done to develop guidelines on the basis of the strongest possible evidence because this allows an accurate description of the quality and/or degree of uncertainty of the recommendations and provides physicians with a valuable tool for judicious decisions. However, creating and updating evidence-based guidelines is extremely costly, and so the nephrological community has been trying to build up a single set of international guidelines under the aegis of Kidney Disease Improving Global Outcomes (KDIGO) [ 1 ]. As part of this unifying effort, the working group responsible for the 2006 update of the National Kidney Foundation–Kidney Disease Outcome Quality Initiative (NKF-KDOQI) guidelines on anaemia management in patients with chronic kidney disease (CKD) [ 2 ], and the 2007 update on haemoglobin (Hb) targets [ 3 ], included members from Europe, Middle East, Mexico and Canada. However, this international effort may not be correctly perceived by European nephrologists, who sometimes feel that differences in practice patterns make it difficult to apply guidelines developed outside Europe; on the other hand, the latest update of the European Best Practice Guidelines (EBPG) [ 4 ] may appear outdated in some respects. A specially appointed ERA-EDTA Work Group met in Paris to discuss European guideline planning in early January 2008, and agreed that the Association should continue producing and updating guidelines in collaboration with KDIGO [ 5 ]. It also agreed that ERA-EDTA should issue suggestions for clinical practice in areas in which evidence is lacking or weak, which will be presented as ‘position statements’ rather than clinical guidelines [ 5 ]. It was also decided to issue position statements about guidelines (recommendations issued by other bodies, of which the current publication is the first result). Finally, the group opted to change the name EBPG to European Renal Best Practice (ERBP) as a means of acknowledging that, especially in nephrology, it is difficult to generate real ‘guidelines’ because of the lack of sufficient evidence. In this context, and while awaiting the publication of the KDIGO anaemia guidelines possibly in 2011, an ad hoc work group was commissioned by the ERBP Advisory Board to give its opinion on the ‘hot topic’ of Hb targets, including recently raised issues that were not covered by KDOQI in 2006 [ 2 ]. These points are summarized in the present position paper, which is not intended to represent a set of new guidelines as it is not the result of a systematic review of the evidence. In May 2006, the NKF published a revised set of guidelines on managing anaemia in CKD [ 2 ]. The Guideline Committee attempted to integrate new evidence using the 2004 EBPG revision [ 4 ] and the 2000 KDOQI guidelines as a starting point [ 6 ]. The update also involved a systematic review of the evidence based on an extensive search of the literature and the grading of the strength of the evidence, and separated evidence-based guidelines, which could be used to measure clinical performance when appropriate, and clinical practice recommendations primarily based on expert judgement. The result was a solid document summarizing the evidence available up until September 2005. In 1997, the DOQI guidelines on anaemia treatment recommended a target range for haematocrit/Hb of between 33% (Hb 11 g/dl) and 36% (Hb 12 g/dl) [ 7 ]. While waiting for the results of clinical trials concerning complete anaemia correction other than Besarab's study [ 8 ], almost similar recommendations were made in the 2000 update of the KDOQI guidelines [ 6 ] and by EBPG [ 4 ] although no upper limit was defined for the early stages of CKD, while normalization of Hb levels was generally not recommended for patients with diabetes or cardiovascular disease. The 2006 update of the NKF-DOQI guidelines recommended that the target Hb range should generally be ≥11.0 g/dl (lower limit) and stated that there was insufficient evidence to recommend routinely maintaining Hb levels of ≥13.0 g/dl in ESA-treated patients (upper limit) [ 2 ]. At this time, the available findings of randomized clinical trials and meta-analysis [ 9 ] did not suggest any major effect of complete anaemia correction on hard, intermediate or surrogate end-points except the quality of life. Two large-scale randomized trials studying the effect of complete anaemia correction on mortality in patients not on dialysis were published in November 2006 [ 10,11 ]. In the CREATE study [ 10 ], 603 patients with stage 3 and 4 CKD and mild–moderate anaemia were randomly assigned to a target Hb range of 13–15 g/dl (normal range) or 10.5–11.5 g/dl (subnormal range). During the 3 years of the study, the number of cardiovascular events was not significantly different between the two groups (58 versus 47) and there was no difference in the frequency of death from any cause or cardiovascular causes, nor in the incidence of hospitalization. However, patients randomized to complete anaemia correction had a shorter time in need of dialysis. The CHOIR study [ 11 ] was an open-label trial in which 1432 CKD patients were randomly assigned to achieve an Hb level of 14.3 g/dl or 11.3 g/dl. The median duration of the follow-up was 16 months, but the trial was stopped early for safety and futility because it had become unlikely that the group randomized to the higher Hb target would obtain any benefit and was associated with an increased risk of reaching the primary composite end-point (death, myocardial infarction or hospitalization because of congestive heart failure or stroke). Despite the differences in their populations and the results of secondary analyses, these two large-scale, prospective randomized trials showed that attempts to correct anaemia completely do not reduce mortality or cardiovascular disease in CKD patients in comparison with partial anaemia correction [ 10,11 ]. A meta-analysis by Phrommintikul et al . [ 12 ] (which also included these two trials) led to the conclusion that the patients in the higher Hb target group were at significantly greater risk of all-cause mortality and arterio-venous access thrombosis. In March 2007, the US Food and Drug Administration (FDA) changed the labelling for erythropoiesis stimulating agents (ESAs) and added a boxed warning stating that Hb targets of >12 g/dl should be avoided because of the increased risk of death and serious cardiac events, and also noted that ESAs should increase Hb only to the lowest level necessary to avoid transfusion. These recommendations created considerable confusion and concern, and the new evidence was considered significant enough to justify updating the statements by the NKF-KDOQI guideline working group concerning Hb targets. An Evidence Review Team analysed all data from randomized controlled trials of anaemia management in CKD, including CREATE [ 10 ], CHOIR [ 11 ] and four additional studies not included in the previous update. Combining mortality outcomes from eight studies involving 3038 subjects with non-dialyzed CKD revealed no difference between the higher and lower Hb target [ 3 ], but combining adverse cardiovascular events from six studies involving 2850 subjects showed an increased risk among the patients assigned to the higher Hb targets (a RR of 1.24, 95% CI 1.02–1.51) [ 3 ], although it is worth noting that the CHOIR and CREATE studies contributed most of the weight to the analysis. Among dialysis patients, combining mortality (four studies, 2391 subjects) or cardiovascular outcomes (three studies, 1975 subjects) showed no statistically significant difference between the higher and lower Hb level; here the study by Besarab et al. [ 8 ] contributed most of the weight to the analysis. The meta-analysis by NKF-KDOQI differed from that by Phrommintikul et al. [ 12 ] as it included studies with a longer minimum follow-up (without any restriction on study size), kept the data concerning dialyzed and non-dialyzed patients separate and had a broader definition of cardiovascular outcomes as it combined all cardiovascular events (Phrommintikul et al. only considered myocardial infarction). On the basis of these results, the NKF-KDOQI working group reformulated its recommendations by stating that the Hb target in patients receiving ESAs should generally be 11–12 g/dl and not >13 g/dl because ‘the possibility of causing harm weighs more heavily than the potential of imp- roving the quality of life and decreasing transfusions’ [ 3 ]. KDIGO, which was established in 2003, is a non-profit foundation governed by an international board that has the aim of ‘improving the care and outcomes of kidney disease patients worldwide by promoting coordination, collaboration and integration of initiatives to develop and implement clinical practices guidelines’. In October 2007, it called a meeting to coordinate a response to the issue of anaemia management after the publication of the NKF-KDOQI update concerning Hb targets [ 13 ]. On the basis of the available evidence, it was concluded that an Hb level of >13 g/ dl may be associated with harm in subjects treated with ESA; that levels of 9.5–11.5 g/dl are associated with better outcomes than those of >13 g/dl, but that there was no evidence either way for intermediate levels (11.5–13 g/dl) in comparison with higher or lower levels. Limitations of the current knowledge of CKD-related anaemia were also identified, as well as topics for future research. It was generally agreed that there were insufficient new data to justify an immediate revision of the anaemia guidelines. On the basis of the anticipated results of key on-going studies, particularly the Trial to Reduce cardiovascular Events with Aranesp(R) (darbepoetin alfa) Therapy (TREAT) [ 14 ], which is a 4000-patient, multicentre, double-blind RCT, designed to determine the impact of anaemia therapy with darbepoetin alpha on mortality and non-fatal cardiovascular events in patients with CKD and type 2 diabetes mellitus, it was planned to start a review of the new evidence no earlier than 2009 with the expectation of completing it in 2011. Given the clear need to avoid duplication, these guidelines will be the result of a coordinated effort undertaken by KDIGO. In 2004, EBPG suggested an Hb target of ≥11 g/dl; values of >14 g/dl were considered undesirable in general, and the limit for patients with cardiovascular disease was set at 12 g/dl. Caution of not exceeding the value of Hb concentrations ≥12 g/dl was recommended to be given also for patients with diabetes, especially if they had concurrent peripheral vascular disease. Since September 2007, when the KDOQI Hb target update was published, no further data from new clinical trials have been published. In response to a request from the editors of the New England Journal of Medicine , the authors of the Normal Hematocrit Study [ 8 ] provided supplementary data about events occurring after the dataset had been analysed by the Independent Data and Safety Monitoring Committee [ 15 ]; the inclusion of these additional events in the survival analysis did not substantially modify the risks of death or myocardial infarction. In the opinion of the ERBP Work Group, it appears reasonable to maintain the lower limit of the target, although the actual evidence for choosing this value is also very limited. On the basis of new evidence, Hb values of 11–12 g/dl should be generally sought in the CKD population without intentionally exceeding 13 g/dl. Although harm is possible when aiming at higher Hb targets, it is likely that this applies most to selected populations such as patients with diabetes and/or clinically significant cardiovascular disease. However, current evidence shows no benefit for higher targets in any subgroup and increased expenditure on higher ESA doses. A secondary analysis of the CHOIR trial showed that patients in the high target group who reached an Hb level of 11 g/dl but could not reach 13 g/dl showed a higher rate of adverse outcomes, and the patients who needed a high ESA dose had a 6% greater risk of reaching a study end-point regardless of the target [ 16 ]. The ERBP Work Group believes that there is a need for better understanding as to whether any harm may be associated with attempts to reach higher Hb values in patients with comorbidities or those who are hyporesponsive to ESAs. It is more difficult to keep patients within a narrow target window mainly because of haemoglobin variability [ 17 ], and so physicians need to accept that patients may be below or above the target for a given period of time. The possibility that there may be a causal relationship between Hb variability and patient outcome has been suggested by association studies [ 18,19 ]. The ERBP Work Group agrees with the recent position of KDIGO [ 13 ] that the available quality of life data vary in quality and are often inconclusive. As more reliable methods of assessing patient-related outcomes and functional status are now available, there is room for new studies testing the effect of anaemia correction on more robust measures of the quality of life. In 2004, EBPG defined anaemia in CKD patients on the basis of their gender and age. In patients living below 1500 m, Hb values were considered below normal if they were <11.5 g/dl in women and <13.5 g/dl in men (<12 g/dl in those aged >70 years), and it was recommended that an anaemia work-up be started when Hb levels fall below these limits. In 2006, KDOQI modified this definition by giving a single criterion for diagnosing anaemia in adult males (Hb <13.5 g/dl, regardless of age) because the decrease in Hb among males aged >60 years is often attributable to concurrent diseases. The ERBP Work Group agrees with this new definition. Traditionally, the most widely used iron tests are serum ferritin and transferrin saturation (TSAT) levels. In 2004, EBPG recommended lower limits of ferritin and TSAT of, respectively, 100 ng/ml and 20%, with target ranges of respectively 200–500 ng/ml and 30–50%. In 2006, and in light of patient safety, KDOQI defined the lower ferritin limit on the basis of CKD status (100 ng/ml in non-HD-CKD and 200 ng/ml in HD-CKD); if serum ferritin levels are >500 ng/ml, iron administration should be discouraged. No key study has been published since the publication of the 2006 KDOQI guidelines, but it is interesting to note the results of the Dialysis Patients’ Response to IV Iron with Elevated Ferritin (DRIVE) trial [ 20 ], which evaluated the efficacy of intravenous ferric gluconate in 134 patients with high ferritin (500–1200 ng/ml) and low transferrin saturation levels (TSAT ≤25%) who were anaemic despite a high rHuEPO dose (≥225 IU/kg/week or ≥22 500 IU/week). After 6 weeks, the patients receiving ferric gluconate (125 mg i.v. at eight consecutive haemodialysis sessions) showed a significant increase in Hb in comparison with controls. However, the study has a number of limitations because, given the short follow-up, it provides no information about safety and iron overload. The ERBP Work Group agrees with the recommendations of the KDOQI guidelines. The 2004 revision of EBPG and the 2006 KDOQI guidelines [ 2 ] made recommendations concerning the use of the three ESAs available at that time: epoetin alpha, epoetin beta and darbepoetin alpha. Since then, two other ESAs have been introduced: epoetin delta and continuous erythropoiesis receptor activator (CERA). Epoetin delta has the same amino acid sequence as endogenous epoetin, and epoetin alpha and beta, but is synthesized in human cells [ 21 ], a process that may theoretically circumvent problems arising from species-dependent differences in protein folding or post-translational modifications. However, such theoretical problems have so far not become obvious and the pharmacodynamics and pharmacokinetics of epoetin delta are also similar to those of other recombinant human erythropoietins [ 22 ]; clinical trials indicate that it corrects renal anaemia in rHuEPO-naive patients [ 23 ] and can be used in the maintenance therapy of those already receiving epoetin alpha [ 24–27 ]. In the opinion of the group, epoetin delta should be administered similarly to epoetin alpha. CERA is a modified recombinant human erythropoietin (rHuEPO) that incorporates a large polyethylene glycol polymer [ 28 ], which increases its molecular weight (∼60 kD) and alters pharmacodynamics and In CERA has a longer than the other ESAs [ ]. It also has a lower for the erythropoietin receptor than epoetin beta, mainly to a much association rate [ ]. These may to its and studies have that it corrects anaemia in patients, and has a recommended starting dose of 2 [ ]. and clinical trials have its for maintenance therapy with a available ESA [ ], and that it can be given 4 i.v. or the maintenance on the evidence available, the frequency of CERA administration should be 2 for correction and 4 for The ERBP Work Group the safety and of CERA to be similar to that of other ESAs. In 2004, the of epoetin alpha in Europe, and that of epoetin beta in European in the way to a of epoetin alpha, the European in it is by three under three different In 2007, epoetin which is of epoetin alpha, as While may some of the current on care the safety of these is much as to the ESAs and they need to be to the same measures as the other ESAs. this it appears that are not used in of other without It is also that ESA are only for intravenous administration in CKD The ERBP Work Group for of epoetin alpha that can be administered only is a but serious adverse to ESA has been an in the number of since mainly associated with the use of the epoetin alpha outside the [ ]. with a change in the of human serum by was by because of the of and it has been that may the of possibly [ ]. it has been suggested that by the of the may with and as an of the The of is an The use of in CKD patients had been in by since and was in and The number of of has since and with no more in may be to a change in the of the of the or the of The the as the most significant and have recently the use of when the vascular access is not available in with an extensive The ERBP Work Group it that are up and are As there were few data concerning the outcome of ESA treatment in patients who have from the 2004 EBPG could not make any about whether to its administration in such In a follow-up concerning CKD patients who developed was made available by the on Drug Events and [ ]. the patients who epoetin after the of epoetin the rate of epoetin was among those who had no at the time of epoetin administration Given these the ERBP Work Group that with ESA can be considered in patients with a of if are no longer It has very recently been that a erythropoietin receptor that is under clinical corrects the anaemia by the of [ ] as in a [ ]. The of erythropoietin receptor in cells has been associated with the that has in and a number of findings to effect is a possible response to and may the of solid However, no relationship between the of on cells and in response to has been The use of ESAs may also increase the risk of in ESA therapy is in patients with who have developed anaemia in to decrease However, safety have been raised in patients since 2004 [ ], particularly in to such as anaemia not secondary to or an Hb target of >12 g/dl. In May 2007, the Advisory Committee of the Food and Drug Administration (FDA) the risks of outcomes and cardiovascular disease in patients receiving [ ], and that boxed for safety information be added to the of the available ESAs the use of the lowest ESA dose to increase Hb to a level high enough to avoid to an Hb target of >12 g/dl should be In the opinion of the ERBP Work Group, ESA therapy should be used in patients with CKD and as no information is available concerning the risk of mortality and in this of Among the and were members of the EBPG Group, which the 2004 update of the EBPG anaemia guidelines. was and was a of the NKF KDOQI working group the 2006 and 2007 was a of the 2007 KDIGO on and are members of the ERBP Advisory members of the ERBP Advisory Board are A A and document has been for to the previous anaemia EBPG Group and the members of the of ERA-EDTA and has been by the Advisory Board of of . is a of the Advisory Board of and from and is a for as an board in and from and and for a from and and as an Advisory Board in and and was a in clinical trials by and from and a from the 2007 KDOQI revision about Hb target [ 3 ]. a from the 2007 KDOQI revision about Hb target [ 3 ].
Authors: F. Locatelli, A. Covic, K.-U. Eckardt, A. Wiecek, R. Vanholder, on behalf of the ERA-EDTA ERBP Advisory Board
Language: English
Subfield: Hematology
Field: Medicine
Open Access status: bronze
OpenAlex ID: W2108858457
FWCI: 12.12
Cites: 48
Cited by: 243
Related to: 10